vs

Side-by-side financial comparison of Live Oak Bancshares, Inc. (LOB) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($225.6M vs $145.5M, roughly 1.6× Live Oak Bancshares, Inc.). Organogenesis Holdings Inc. runs the higher net margin — 19.4% vs 19.2%, a 0.2% gap on every dollar of revenue. On growth, Organogenesis Holdings Inc. posted the faster year-over-year revenue change (78.1% vs 18.4%). Over the past eight quarters, Organogenesis Holdings Inc.'s revenue compounded faster (43.2% CAGR vs 7.7%).

Live Oak Bank, a subsidiary of Live Oak Bancshares, Inc., is an American bank. Headquartered in Wilmington, North Carolina, it serves small business owners in all 50 states and was the leading SBA 7(a) lender by dollar volume in 2022.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

LOB vs ORGO — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.6× larger
ORGO
$225.6M
$145.5M
LOB
Growing faster (revenue YoY)
ORGO
ORGO
+59.8% gap
ORGO
78.1%
18.4%
LOB
Higher net margin
ORGO
ORGO
0.2% more per $
ORGO
19.4%
19.2%
LOB
Faster 2-yr revenue CAGR
ORGO
ORGO
Annualised
ORGO
43.2%
7.7%
LOB

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
LOB
LOB
ORGO
ORGO
Revenue
$145.5M
$225.6M
Net Profit
$27.9M
$43.7M
Gross Margin
Operating Margin
28.1%
Net Margin
19.2%
19.4%
Revenue YoY
18.4%
78.1%
Net Profit YoY
187.6%
469.5%
EPS (diluted)
$0.60
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LOB
LOB
ORGO
ORGO
Q1 26
$145.5M
Q4 25
$161.9M
$225.6M
Q3 25
$146.1M
$150.9M
Q2 25
$143.7M
$101.0M
Q1 25
$126.1M
$86.7M
Q4 24
$116.9M
$126.7M
Q3 24
$129.9M
$115.2M
Q2 24
$125.5M
$130.2M
Net Profit
LOB
LOB
ORGO
ORGO
Q1 26
$27.9M
Q4 25
$46.2M
$43.7M
Q3 25
$26.5M
$21.6M
Q2 25
$23.4M
$-9.4M
Q1 25
$9.7M
$-18.8M
Q4 24
$9.9M
$7.7M
Q3 24
$13.0M
$12.3M
Q2 24
$27.0M
$-17.0M
Gross Margin
LOB
LOB
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
LOB
LOB
ORGO
ORGO
Q1 26
Q4 25
38.2%
28.1%
Q3 25
25.0%
13.7%
Q2 25
21.7%
-12.5%
Q1 25
10.4%
-30.9%
Q4 24
11.3%
8.1%
Q3 24
13.7%
5.4%
Q2 24
28.7%
-10.7%
Net Margin
LOB
LOB
ORGO
ORGO
Q1 26
19.2%
Q4 25
28.5%
19.4%
Q3 25
18.1%
14.3%
Q2 25
16.3%
-9.3%
Q1 25
7.7%
-21.7%
Q4 24
8.5%
6.1%
Q3 24
10.0%
10.7%
Q2 24
21.5%
-13.1%
EPS (diluted)
LOB
LOB
ORGO
ORGO
Q1 26
$0.60
Q4 25
$0.96
$0.31
Q3 25
$0.55
$0.11
Q2 25
$0.51
$-0.10
Q1 25
$0.21
$-0.17
Q4 24
$0.22
$0.05
Q3 24
$0.28
$0.09
Q2 24
$0.59
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LOB
LOB
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$93.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.3B
$300.1M
Total Assets
$15.3B
$598.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LOB
LOB
ORGO
ORGO
Q1 26
Q4 25
$93.7M
Q3 25
$63.7M
Q2 25
$73.1M
Q1 25
$110.0M
Q4 24
$135.6M
Q3 24
$94.3M
Q2 24
$89.9M
Total Debt
LOB
LOB
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
LOB
LOB
ORGO
ORGO
Q1 26
$1.3B
Q4 25
$1.2B
$300.1M
Q3 25
$1.2B
$255.1M
Q2 25
$1.1B
$233.2M
Q1 25
$1.0B
$242.9M
Q4 24
$999.0M
$262.9M
Q3 24
$1.0B
$278.5M
Q2 24
$961.0M
$263.5M
Total Assets
LOB
LOB
ORGO
ORGO
Q1 26
$15.3B
Q4 25
$15.1B
$598.7M
Q3 25
$14.7B
$509.8M
Q2 25
$13.8B
$461.1M
Q1 25
$13.6B
$467.4M
Q4 24
$12.9B
$497.9M
Q3 24
$12.6B
$446.3M
Q2 24
$11.9B
$443.2M
Debt / Equity
LOB
LOB
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LOB
LOB
ORGO
ORGO
Operating Cash FlowLast quarter
$39.4M
Free Cash FlowOCF − Capex
$34.8M
FCF MarginFCF / Revenue
15.4%
Capex IntensityCapex / Revenue
2.1%
Cash ConversionOCF / Net Profit
0.90×
TTM Free Cash FlowTrailing 4 quarters
$-24.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LOB
LOB
ORGO
ORGO
Q1 26
Q4 25
$158.2M
$39.4M
Q3 25
$62.3M
$3.1M
Q2 25
$49.2M
$-32.9M
Q1 25
$-33.0M
$-19.9M
Q4 24
$156.8M
$10.9M
Q3 24
$47.4M
$8.7M
Q2 24
$29.5M
$4.7M
Free Cash Flow
LOB
LOB
ORGO
ORGO
Q1 26
Q4 25
$143.5M
$34.8M
Q3 25
$60.6M
$844.0K
Q2 25
$47.8M
$-36.5M
Q1 25
$-35.3M
$-23.6M
Q4 24
$107.5M
$7.6M
Q3 24
$41.0M
$6.1M
Q2 24
$12.3M
$2.9M
FCF Margin
LOB
LOB
ORGO
ORGO
Q1 26
Q4 25
88.6%
15.4%
Q3 25
41.4%
0.6%
Q2 25
33.3%
-36.1%
Q1 25
-28.0%
-27.2%
Q4 24
91.9%
6.0%
Q3 24
31.6%
5.3%
Q2 24
9.8%
2.2%
Capex Intensity
LOB
LOB
ORGO
ORGO
Q1 26
Q4 25
9.1%
2.1%
Q3 25
1.2%
1.5%
Q2 25
1.0%
3.6%
Q1 25
1.8%
4.2%
Q4 24
42.2%
2.7%
Q3 24
4.9%
2.2%
Q2 24
13.7%
1.4%
Cash Conversion
LOB
LOB
ORGO
ORGO
Q1 26
Q4 25
3.42×
0.90×
Q3 25
2.35×
0.14×
Q2 25
2.10×
Q1 25
-3.39×
Q4 24
15.84×
1.43×
Q3 24
3.64×
0.71×
Q2 24
1.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons